Elotuzumab ( —— )

产品货号. M34757 CAS No. 915296-00-3

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

产品询价大包装询价加入购物车

产品名称

Elotuzumab
注意事项

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
产品简述

Elotuzumab 是一种针对 SLAMF7 受体的单克隆抗体。当作为复发或难治性多发性骨髓瘤 (RRMM) 的单一活性分子给予时，Elotuzumab 没有显着的抗骨髓瘤活性。与其他抗骨髓瘤活性分子联合使用时，Elotuzumab 可改善反应和结果。
产品描述

Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents.
体外实验

——
体内实验

——
同义词

——
通路

Others
靶点

Other Targets
受体

Others
研究领域

——
适应症

——

1. Magen H, et al. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016;7(4):187-195.

计算器

产品手册

关联产品

DL-Serine

DL-丝氨酸是一种非必需氨基酸，也是丙酮酸激酶 M2 的天然配体和变构激活剂。
VIR-165

VIR-165 is a modified form of virus inhibitory peptide (VIRIP), which corresponds to residues 353 to 372 of C-proximal region of human alpha1-antitrypsin, the most abundant circulating serine protease inhibitor. VIRIP inhibits a wide variety of human immunodeficiency virus type 1 (HIV-1) strains.
Platelet-Derived Gro...

Platelet-Derived Growth Factor Receptor Substrate 1; PDGF Receptor Substrate